-
Virginia G. Piper Cancer Center, TGen Studying New Breast Cancer Drug
7/25/2011
A new drug targeting the PI3K gene in patients with advanced breast cancer shows promising results in an early phase I investigational study conducted at Virginia G. Piper Cancer at Scottsdale Healthcare, according to a presentation by oncologist Dr. Daniel D. Von Hoff at the 47th annual meeting of the American Society of Clinical Oncology (ASCO).
-
Phase III Trial Of Novartis Drug Afinitor Met Primary Endpoint Of Reducing SEGA Tumor Size In Patients With Tuberous Sclerosis
7/15/2011
Novartis announced recently Phase III trial results that showed more than one-third of patients taking Afinitor (everolimus) tablets experienced a 50% or greater reduction in the size of their subependymal giant cell astrocytomas (SEGAs), non-cancerous brain tumors associated with tuberous sclerosis complex (TSC).
-
Key Alzheimer's Drug Development Stakeholders Join Forces To Establish Clinical Trial Safeguards And Accelerate Discovery
7/13/2011
New recommendations to protect participant safety in clinical trials of certain Alzheimer's disease drugs have been accepted by the U.S. Food and Drug Administration (FDA) and are already being incorporated into research studies.
-
Data From Phase 1 Study Of NKTR-181 Demonstrate Proof-Of-Concept For Nektar's Novel Opioid Analgesic Candidate
6/7/2011
Nektar Therapeutics (NASDAQ: NKTR) announced today positive interim data from an ongoing single-dose Phase 1 clinical trial evaluating NKTR-181, the company's novel mu-opioid analgesic candidate.
-
Adeona Announces Positive Alzheimer's Subgroup Analysis That Supports Additional Clinical Study Of Proprietary Zinc-Based Therapy
6/2/2011
Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of innovative medicines for serious central nervous system diseases, announced today positive findings based on further analyses from the clinical study evaluating reaZin along with near-term plans for its Alzheimer's disease program.